Targeted inhibition of MCT4 (phloretin, α-cyano-4-hydroxycinnamate, and AR-C155858) and SLC5A12 (anti-Slc5a12 antibody and shRNAs) inhibits the motility of CD8+ and CD4+ T cells, respectively, by reducing lactate and lactic acid concentrations in the extracellular space, thus reducing disease severity in mouse models of rheumatoid arthritis [129]. This evidence concerns the gene CD8A and rheumatoid arthritis.